Benefit of treatment of latent tuberculosis infection in individual patients

Claudia C. Dobler, Andrew Martin, Guy B. Marks

Research output: Contribution to journalArticleResearchpeer-review

7 Citations (Scopus)

Abstract

We aimed to develop a decision aid that estimates whether treatment of latent tuberculosis infection (LTBI) is likely to have a net gain in quality-adjusted life-years for an individual. A Markov model was developed which incorporated personalised estimates for risk of tuberculosis (TB) reactivation, TB death, quality-of-life impairments and treatment side-effects. The net effect of LTBI treatment was quantified in terms of quality-adjusted life-years gained or lost. Analyses were conducted for a representative set of hypothetical patients. LTBI treatment was estimated to be beneficial when the annual risk of TB reactivation exceeded 13/100 000 to 93/100 000 for females aged 10-75 years and 15/100 000 to 119/100 000 for males aged 10-75 years; the numbers needed to treat to avoid one case of TB were 93, 77, 85 and 72, respectively, at these threshold levels. LTBI treatment was estimated to confer a positive net benefit across a broad range of patients with characteristics typically seen in a low incidence setting for TB. Use of the decision aid has the potential to facilitate and increase confidence with LTBI treatment decisions by providing clinicians and patients with personalised estimates of likely net benefit.

Original languageEnglish
Pages (from-to)1397-1406
Number of pages10
JournalEuropean Respiratory Journal
Volume46
Issue number5
DOIs
Publication statusPublished - 1 Nov 2015
Externally publishedYes

Fingerprint

Latent Tuberculosis
Tuberculosis
Quality-Adjusted Life Years
Decision Support Techniques
Therapeutics
Numbers Needed To Treat
Quality of Life
Incidence

Cite this

@article{1cdd41b15ce64429981eb8ab29b01d97,
title = "Benefit of treatment of latent tuberculosis infection in individual patients",
abstract = "We aimed to develop a decision aid that estimates whether treatment of latent tuberculosis infection (LTBI) is likely to have a net gain in quality-adjusted life-years for an individual. A Markov model was developed which incorporated personalised estimates for risk of tuberculosis (TB) reactivation, TB death, quality-of-life impairments and treatment side-effects. The net effect of LTBI treatment was quantified in terms of quality-adjusted life-years gained or lost. Analyses were conducted for a representative set of hypothetical patients. LTBI treatment was estimated to be beneficial when the annual risk of TB reactivation exceeded 13/100 000 to 93/100 000 for females aged 10-75 years and 15/100 000 to 119/100 000 for males aged 10-75 years; the numbers needed to treat to avoid one case of TB were 93, 77, 85 and 72, respectively, at these threshold levels. LTBI treatment was estimated to confer a positive net benefit across a broad range of patients with characteristics typically seen in a low incidence setting for TB. Use of the decision aid has the potential to facilitate and increase confidence with LTBI treatment decisions by providing clinicians and patients with personalised estimates of likely net benefit.",
author = "Dobler, {Claudia C.} and Andrew Martin and Marks, {Guy B.}",
year = "2015",
month = "11",
day = "1",
doi = "10.1183/13993003.00577-2015",
language = "English",
volume = "46",
pages = "1397--1406",
journal = "European Journal of Respiratory Diseases",
issn = "0903-1936",
publisher = "EUROPEAN RESPIRATORY SOC JOURNALS LTD",
number = "5",

}

Benefit of treatment of latent tuberculosis infection in individual patients. / Dobler, Claudia C.; Martin, Andrew; Marks, Guy B.

In: European Respiratory Journal, Vol. 46, No. 5, 01.11.2015, p. 1397-1406.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Benefit of treatment of latent tuberculosis infection in individual patients

AU - Dobler, Claudia C.

AU - Martin, Andrew

AU - Marks, Guy B.

PY - 2015/11/1

Y1 - 2015/11/1

N2 - We aimed to develop a decision aid that estimates whether treatment of latent tuberculosis infection (LTBI) is likely to have a net gain in quality-adjusted life-years for an individual. A Markov model was developed which incorporated personalised estimates for risk of tuberculosis (TB) reactivation, TB death, quality-of-life impairments and treatment side-effects. The net effect of LTBI treatment was quantified in terms of quality-adjusted life-years gained or lost. Analyses were conducted for a representative set of hypothetical patients. LTBI treatment was estimated to be beneficial when the annual risk of TB reactivation exceeded 13/100 000 to 93/100 000 for females aged 10-75 years and 15/100 000 to 119/100 000 for males aged 10-75 years; the numbers needed to treat to avoid one case of TB were 93, 77, 85 and 72, respectively, at these threshold levels. LTBI treatment was estimated to confer a positive net benefit across a broad range of patients with characteristics typically seen in a low incidence setting for TB. Use of the decision aid has the potential to facilitate and increase confidence with LTBI treatment decisions by providing clinicians and patients with personalised estimates of likely net benefit.

AB - We aimed to develop a decision aid that estimates whether treatment of latent tuberculosis infection (LTBI) is likely to have a net gain in quality-adjusted life-years for an individual. A Markov model was developed which incorporated personalised estimates for risk of tuberculosis (TB) reactivation, TB death, quality-of-life impairments and treatment side-effects. The net effect of LTBI treatment was quantified in terms of quality-adjusted life-years gained or lost. Analyses were conducted for a representative set of hypothetical patients. LTBI treatment was estimated to be beneficial when the annual risk of TB reactivation exceeded 13/100 000 to 93/100 000 for females aged 10-75 years and 15/100 000 to 119/100 000 for males aged 10-75 years; the numbers needed to treat to avoid one case of TB were 93, 77, 85 and 72, respectively, at these threshold levels. LTBI treatment was estimated to confer a positive net benefit across a broad range of patients with characteristics typically seen in a low incidence setting for TB. Use of the decision aid has the potential to facilitate and increase confidence with LTBI treatment decisions by providing clinicians and patients with personalised estimates of likely net benefit.

UR - http://www.scopus.com/inward/record.url?scp=84946599897&partnerID=8YFLogxK

U2 - 10.1183/13993003.00577-2015

DO - 10.1183/13993003.00577-2015

M3 - Article

VL - 46

SP - 1397

EP - 1406

JO - European Journal of Respiratory Diseases

JF - European Journal of Respiratory Diseases

SN - 0903-1936

IS - 5

ER -